Given the rarity of SAMS, the demonstration of activating KRAS variants in three separate patients who all demonstrated significant clinical responses to MEK inhibition suggests a central role of KRAS in the pathophysiology of SAMS. Here, KRAS is linked to short stature-auditory canal atresia-mandibular hypoplasia-skeletal anomalies syndrome.